These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38972107)

  • 1. Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study.
    Tunç A; Yetkin MF; Seferoğlu M; İnanç Y; Sıvacı AÖ; Türkoğlu ŞA; Baydar C; Güzel V; Bülbül NG; Sezer V; Altun Y
    Mult Scler Relat Disord; 2024 Aug; 88():105757. PubMed ID: 38972107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
    Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'Maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; Macdonell RA; Aguera-Morales E; Cabre P; Ben NH; Van der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; de Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T;
    Neurology; 2022 Oct; 99(17):e1926-e1944. PubMed ID: 35977837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment.
    Pantazou V; Pot C; Du Pasquier R; Le Goff G; Théaudin M
    Mult Scler Relat Disord; 2021 Jun; 51():102918. PubMed ID: 33838521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
    Derfuss T; Bergvall NK; Sfikas N; Tomic DL
    Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
    Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'Maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; Macdonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
    JAMA Neurol; 2023 Jul; 80(7):739-748. PubMed ID: 37273217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
    Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
    Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
    Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Salzer J
    Eur J Neurol; 2019 Aug; 26(8):1060-1067. PubMed ID: 30762259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
    Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
    Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U
    Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.